Analyst firms · BofA Securities · HAE

BofA Securities HAE price target and rating history

Haemonetics Corporation (HAE) · Health Care

BofA Securities rates Haemonetics Corporation (HAE) Buy with a $80 price target, as of its latest action on May 22, 2026. It has published 3 rating actions on HAE since September 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a HAE price target in the last 12 months, the median target is $106. BofA Securities's $80 is 25% below that.

Current rating
Buy
Price target
$80
Median target, all firms
$106
Actions on HAE
3

BofA Securities price target on HAE

$85$77$6820252026
BofA Securities price target on HAE, each point a stated target, September 2024 to May 2026.

Every BofA Securities rating on HAE

How other firms rate HAE

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
JefferiesBuy$150Nov 13, 2026
CitigroupBuy$123Sep 17, 2026
BofA SecuritiesBuy$80May 22, 2026
Barrington ResearchOutperform$89May 12, 2026
NeedhamHoldDec 15, 2025

Questions about BofA Securities and HAE

What is BofA Securities's price target for HAE?
BofA Securities's latest stated price target for Haemonetics Corporation (HAE) is $80, from its action on May 22, 2026.
What is BofA Securities's rating on HAE?
BofA Securities rates HAE Buy, a bullish rating, as of May 22, 2026.
When did BofA Securities last change its view on HAE?
On May 22, 2026, BofA Securities upgrades to Buy from Neutral, price target $80.
How does BofA Securities's HAE target compare with other analysts?
Across 4 firms with a HAE price target in the last 12 months, the median target is $106. BofA Securities's $80 is 25% below that.

More HAE rating histories

All BofA Securities ratingsHAE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.